News

Æterna Zentaris has reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with Cetrorelix Pamoate. Study Z-036 did not reach its primary

The Dow Chemical has formed a new independent company known as Pfenex through its Dow Venture Capital group. The new company, headquartered in San Diego, California, is based

Genzyme has presented data from its CAM314 randomised Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with

RCT licensee, Dyax has received approval from the FDA for Kalbitor (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age

BioLife Solutions has entered into a license and custom cGMP manufacturing agreement with Centocor Research & Development. The agreement includes the production of a custom variant of BioLife’s

Novo Nordisk has initiated its first Phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a $2m payment to Merrion whose Gipet technology is

Alethia Biotherapeutics (Alethia) has obtained the exclusive worldwide diagnostic rights to a peptide that specifically binds to tumor-associated clusterin from the National Research Council Biotechnology Research Institute (NRC-BRI)

Medco Health Solutions (Medco) has reported that its majority-owned subsidiary, Europa Apotheek Venlo, has acquired shop-apotheke.com, an online OTC and healthcare products site. The combined businesses intend to

Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to